Cariprazine Depot

Phase 2Small molecule

MMapi Pharma Ltd.

Cariprazine Depot is one of 2 small molecule programs targeting Long-Acting Injection. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Long-Acting InjectionRecruiting

Long-Acting InjectionPhase 2

Recruiting

Competition

Competitive Landscape

1 competitor in Long-Acting Injection

#DrugCompanyPhaseTrials

Vraylar

AbbVie

Phase 2

1 2

Cariprazine Depot

MMapi Pharma Ltd.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1/2Recruiting

Long-Acting Injection

NCT07185815

Clinical

Trials by Indication[1]

Long-Acting Injection1 trial

Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine

Recruiting·MMapi Pharma Ltd.·Phase 1/2·NCT07185815·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cariprazine Depot. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cariprazine Depot compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cariprazine Depot. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mapi Pharma Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMapi Pharma Ltd.

Cariprazine Depot

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Long-Acting Injection1 trial

References

Drug Info

Quick Facts

Related News